JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 85.0%

Neg 85% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.